Infrared Photobiomodulation for Drug-Resistant Epilepsy
This study is exploring a new treatment for drug-resistant epilepsy, a condition where seizures continue despite medication. The treatment involves wearing a hat with infrared lights (photobiomodulation) for 30 minutes daily over six months. Researchers want to see if this treatment can reduce your seizure rate and how comfortable it is to use. You might be able to join if you are 18 or older, have drug-resistant epilepsy with at least two seizures per month, and have kept an accurate seizure diary for at least three months. This treatment has shown promise in animal studies, but this is the first time it's being tested in humans. The study is currently unclear on its recruitment status.
- Study design
- This is an interventional study with a planned enrollment of 13 participants. All participants will receive the photobiomodulation device.
- What's involved
- You would wear a hat with infrared lights for 30 minutes daily for six months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your seizure rate reduction and tolerability will be measured at six months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Infrared Photobiomodulation in Humans With Epilepsy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Daniel Goldenholz, MD PhD · PRINCIPAL_INVESTIGATOR · Beth Israel Deaconess Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- seizure rate reduction6 months
fraction of seizures reduced by therapy assessed by individual baseline rate
- tolerability of daily photobiomodulation6 months
Do participants find it reasonable to use the therapy daily or do they request exiting from the study? Do participants report significant side effects as reported by weekly check-ins that make the therapy uncomfortable or intolerable?